Note: Single-source report; awaiting corroboration.
Researchers at the National Institutes of Health (NIH) have identified rare monoclonal antibodies that may help prevent or treat alpha-gal syndrome (AGS), an allergic condition triggered by tick bites. AGS causes allergic reactions to galactose-α-1,3-galactose (alpha-gal), a molecule found in red meat and other mammalian products. The condition is increasing in prevalence and currently lacks specific treatments beyond red meat avoidance, according to NIH's National Institute of Allergy and Infectious Diseases (NIAID).
In laboratory experiments, the newly discovered antibodies acted as a biological shield by blocking human IgE antibodies from binding to alpha-gal allergens. This blockage could prevent allergic reactions in people with AGS. Researchers originally sought antibodies targeting alpha-gal on malaria parasites but found these antibodies did not strongly bind to the parasite. They then evaluated whether the antibodies could counteract AGS allergens and identified 13 that could bind them. Among these, two antibodies blocked IgE binding from AGS patient samples, and one interfered with basophil activation, an immune response involved in allergies.
The findings suggest a potential path for developing targeted therapies before individuals develop AGS. Since 2010, about 110,000 suspected cases have been reported in the U.S., though the true number may be higher due to underdiagnosis. Current management focuses on avoidance of triggers, as no approved treatments or cures exist.